<DOC>
	<DOCNO>NCT02956590</DOCNO>
	<brief_summary>This trial pitavastatin determine efficacy safety high risk population provide evidence clinician target treatable risk factor achieve impact early atherosclerosis , potentially achieve primary prevention adult cardiovascular disease .</brief_summary>
	<brief_title>Dyslipidemia Obesity Intervention Teens</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled clinical trial pitavastatin 2 year compare effect study drug versus placebo vascular measure least 354 obese ( body mass index &gt; 95th percentile ) adolescent CDO ( define high non-HDL-C + high TG/HDL-C ratio low HDL-C ) . Enrollment take place 18 month .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Boys girl age 10 17 year ( 2 year availability study participation ) BMI &gt; 95th percentile ( use CDC BMI chart ) Fasting lipid profile x2 follow : LDLC &lt; 160 mg/dL , TG &lt; 500 mg/dL , TG/HDLC ratio &gt; 3.0 HDLC &lt; 45 mg/dL boy HDLC &lt; 50 mg/dL girl , nonHDLC &gt; 145 mg/dL Participant consent , parental/guardian consent participant assent Participant fluency English Current use lipid lower medication , antihypertensive medication , growth hormone , systemic corticosteroid , cyclosporine , protease inhibitor , colchicine , warfarin , second generation psychotropic drug , oral isotretinoin ; stable dos stimulant antidepressant therapy accept Female pregnant , plan become pregnant sexually active without contraception Stage 2 hypertension ( systolic diastolic blood pressure 99th percentile age , sex height percentile + 5 mmHg ; confirm appropriate evaluation ) Diabetes ( type 1 type 2 ) American Diabetes Association criterion ( fast glucose &gt; 126 mg/dL , random glucose &gt; 200 mg/dL , 2hour oral glucose tolerance test glucose &gt; 200 mg/dL ) Prediabetes polycystic ovary syndrome insulin sensitize therapy Known renal insufficiency Uncontrolled thyroid disease Proteinuria suggestive renal disease ( urine protein : creatinine &gt; 0.2 ) Syndromic patient patient neurocognitive delay preclude adherence study drug Liver disease nonalcoholic fatty liver disease ( NAFLD ) either diagnose suggested alanine amiotransferase ( ALT ) ≥ 50 U/L , severe NAFLD indicate ALT ≥ 200 U/L Unexplained persistent elevated creatine kinase ( CK ) level &gt; 3x upper limit normal Plans leave geographic area completion anticipate 2 year trial participation Any unstable medical emotional condition chronic disease would preclude follow protocol impact valid vascular measurement Admits current smoking</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>dyslipidemia</keyword>
	<keyword>obesity</keyword>
	<keyword>pitavastatin</keyword>
	<keyword>lipid</keyword>
</DOC>